¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"alpha feedback"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • alpha wave
    ¾ËÆÄÆÄ ³úÆÄ(Òà÷î)ÀÇ .
  • alpha-1-antittrypsin deficiensy
    ¾ËÆÄ-1-¾ÈƼƮ¸³½Å °áÇÌÁõ(¡­ÌÀù¹ñø)
  • alpha-2-macroglobulin
    ¾ËÆÄ-2-¸¶Å©·Î±Û·ÎºÒ¸°
  • alpha-adrenal receptor antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸°¼ö¿ëüÂ÷´ÜÁ¦
  • alpha-adrenergic agonist
    ¾ËÆÄ¾Æµå·¹³¯¸°ÃËÁøÁ¦
  • alpha-adrenergic antagonist
    ¾ËÆÄ¾Æµå·¹³¯¸°±æÇ×Á¦
  • alpha-adrenergic receptor
    ¾ËÆÄ-¾Æµå·¹³¯¸°¼ö¿ëü.
  • alpha-adrenergic receptor
    ¾ËÆÄ¾Æµå·¹³¯¸°¼ö¿ëü
  • alpha-amino acid nitrogen
    ¾ËÆÄ-¾Æ¹Ì³ë»êÁú¼Ò
  • alpha-chain disease
    ¾ËÆÄ¼â Áúȯ(¡­áð òðü´)
  • alpha-chymotrypsin
    ¾ËÆÄÄ«ÀÌ¸ðÆ®¸³½Å
  • alpha-fetoprotein
    ¾ËÆÄžƴܹé
  • alpha-fetoprotein
    ¾ËÆÄ-žƴܹé(¡­÷Ãä®Ó±ÛÜ)
  • alpha-fucosidase
    ¾ËÆÄ-ǪÄڽôÙÁ¦(¡­ð¥)
  • alpha-ketoglutarate
    ¾ËÆÄ-ÄÉÅä±Û·çŸ·¹ÀÌÆ®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • alpha fetoprotein =AFP
    ¾ËÆÄžƴܹé(¡­÷Ãä®Ó±ÛÜ).
  • alpha fiber
    ¾ËÆÄ(½Å°æ)¼¶À¯
  • alpha granule
    ¾ËÆÄ °ú¸³(¡­Î¨Ø£)
  • alpha hemolysis
    ¾ËÆÄ¿ëÇ÷(¡­éÁúì).
  • alpha hemolysis
    ¾ËÆÄ¿ëÇ÷(¡­éÁúì).
  • alpha hydroxy acids
    ¾ËÆÄÈ÷µå·Ï½Ã»ê
  • alpha motoneuron
    ¾ËÆÄ¿îµ¿´º¿ì·Ð
  • alpha particle
    ¾ËÆÄÀÔÀÚ
  • alpha ray
    ¾ËÆÄ¼±
  • alpha rhythm
    ¾ËÆÄ¸®µë ³úÆÄ(Òà÷î)ÀÇ .
  • alpha thalassemia
    ¾ËÆÄÅ»¶ó¼¼¹Ì¾Æ.
  • alpha thalassemia
    ¾ËÆÄÁöÁßÇØºóÇ÷
  • alpha thalassemia
    ¾ËÆÄÅ»¶ó¼¼¹Ì¾Æ.
  • alpha toxin
    ¾ËÆÄ µ¶¼Ò (¡­Ô¸áÈ)
  • alpha wave
    ¾ËÆÄÆÄ ³úÆÄ(Òà÷î)ÀÇ .
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
FM face mask; facilities management; family medicine; feedback mechanism; fetal movement; fibromuscular...
FR failure rate; film-screen radiograph; fasciculus retroflexus; febrile reaction; feedback regulation;...
QFES Quality Feedback Expert System
SAF scrapie-associated fibrils; self-articulating femoral; serum accelerator factor; simultaneous audito...
SFT Sabin-Feldman test; sensory feedback therapy; skinfold thickness
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
20 alpha-DH-P 20 alpha-dihydro-progesterone
20 alpha-OHP 20 alpha-dihydro-progesterone
20 alpha-OH-P 20 alpha-hydroxy-4-pregnan-3-one
20 alpha-SDH 20 alpha-hydroxysteroid dehydrogenase
3 alpha-HSD 3 Alpha-hydroxysteroid dehydrogenase
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • alpha-galactosidase
    ¾ËÆÄ-°¥¶ôÅä½Ã´Ù¾ÆÁ¦
  • alpha-l-iduronidase
    a-L-Iduronidase
  • alpha-oxynaphthoic acid
    ¾ËÆÄ-¿Á½Ã³ªÇÁÅä»ê
    °áÁ¤¼ºÀÇ »ê,OHC10H6COOH.°ú°Å¿¡´Â ¹æºÎÁ¦, ¹æÃëÁ¦·Î »ç¿ëµÇ¾ú´Ù.
  • { alpha }`_{2 } ^{A } { gamma }`_{ 2} ^{F }

    ¶ó°í ±âÀçµÈ´Ù. Çì¸ð±Û·Îºó A(¼ºÀÎ Çì¸ð±Û·Îºó)´Â º¸Åë ¼ºÀÎÀÇ ´ëºÎºÐÀÌ µÇ¸ç,
    ¿ëÇ÷¼º
    Çì¸ð±Û·ÎºóÀÌ ÀûÇ÷±¸¿¡¼­ À¯¸®ÇÏ¿© Ç÷ÀåÁß¿¡ ³ªÅ¸³ª´Â ¼ºÁú.
  • myelinated A alpha mechanoreceptor
    À¯¼öÃÊ A-¾ËÆÄ ±â°è ¼ö¿ëü, À¯¼öÃÊ A-¾ËÆÄ ±â°è ¼ö¿ë±â
  • CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
    alpha-1,4-glucan lyase <enzyme> Degrades alpha-1,4-glucan to produce 1,5-anhydrofructose; from seaweeds gracilariopsis lemaneiformis and gracilaria verrucosa; mw 111 kD; amino acid sequence has been determined
    Registry number: EC 4.2.2.-
    Synonym: alpha-1,4-glucan 4-lyase
    (26 Jun 1999)
    alpha 1-4-mannosyltransferase <enzyme> From mycobacterium smegmatis; involved in methylmannose polysaccharide elongation; GDP-mannose is donor
    Registry number: EC 2.4.1.-
    (26 Jun 1999)
    alpha(1-6)mannosidase <enzyme> Human lysosomal enzyme highly specific for alpha 1-6 mannose residues; inhibited by swainsonine; not the same enzyme which is deficient in alpha-mannosidosis
    Registry number: EC 3.2.1.-
    (26 Jun 1999)
    alpha 1,6-mannosyltransferase <enzyme> From saccharomyces cerevisiae; adds mannose residues in an alpha-1,6-linkage to man8glcnac and man9glcnac in the biosynthesis of the outer chain of yeast mannoproteins
    Registry number: EC 2.4.1.-
    (26 Jun 1999)
    alpha-1 antichymotrypsin <chemical> Glycoprotein found in alpha(1)-globulin region in human serum. It is an inhibiter of the digestive protease, chymotrypsin and other chymotrypsin-like proteinases in vivo and has cytotoxic killer-cell activity in vitro.
    The protein also has a role as an acute-phase protein and is active in the control of immunologic and inflammatory processes, and as a tumour marker. It is a member of the serpin superfamily.
    Pharmacological action: serine proteinase inhibitors.
    (12 Dec 1998)
    alpha-1 antitrypsin <chemical> Plasma glycoprotein member of the serpin superfamily which inhibits trypsin, neutrophil elastase, and other proteolytic enzymes. Commonly referred to as alpha 1-proteinase inhibitor (a1pi), it exists in over 30 different biochemical variant forms known collectively as the pi (protease inhibitor) system.
    Hereditary deficiency is associated with pulmonary emphysema.
    See: alpha-1 antitrypsin deficiency
    Pharmacological action: serine proteinase inhibitors, trypsin inhibitors.
    (12 Dec 1998)
    alpha-1 antitrypsin deficiency <chest medicine> Deficiency of the protease inhibitor alpha-1 antitrypsin, leads primarily to degradation of elastin of the alveolar walls, as well as other structural proteins of a variety of tissues.
    The lack of this protein leads to damage of various organs, but mainly to the lung and liver.
    symptoms may become apparent at a very early age or in adulthood, manifesting either as shortness of breath or liver related symptoms (jaundice, fatigue, fluid in the abdomen, mental changes, or gastrointestinal bleeding). There are several options for treatment of the lung disease, including replacement of the missing protein. Treatment of the liver disease is a well-timed liver transplant
    (12 Dec 1998)
    alpha-1-proteinase deficiency Absence of a serum proteinase inhibitor that may cause nodular non-suppurative panniculitis.
    (05 Mar 2000)
    alpha(2,8)-sialyltransferase <enzyme> Active towards gm1b, gd1a, gt1b, and gd3 gangliosides; genbank u91641
    Registry number: EC 3.4.99.-
    Synonym: st8sia v, hst8sia v
    (26 Jun 1999)
    alpha-(4-O-methyl)-D-glucuronidase <enzyme> Removes 4-o-methyl-glucopyranosyl uronic acid residues from the 2-position of fungal cell wall xylans
    Registry number: EC 3.2.1.-
    Synonym: 4-o-methyl-glucuronidase
    (26 Jun 1999)
    alpha-acetolactic acid An intermediate in pyruvic acid catabolism and valine biosynthesis; CH3COC(OH)(CH3)-COOH.
    (05 Mar 2000)
    alpha-actinin An F-actin binding protein in vertebrate cells that cross-links actin filaments into regular parallel arrays.
    (05 Mar 2000)
    alpha-adrenergic blocking agent An agent that competitively blocks alpha-adrenergic receptors; used in the treatment of hypertension.
    Synonym: alpha-blocker.
    (05 Mar 2000)
    alpha-adrenergic receptors Adrenergic receptor's in effector tissues capable of selective activation and blockade by drugs; conceptually derived from the ability of certain agents, such as phenoxybenzamine, to block only some adrenergic receptor's and of other agents, such as methoxamine, to activate only the same adrenergic receptor's. Such receptor's are designated as alpha-receptors. Their activation results in physiological responses such as increased peripheral vascular resistance, mydriasis, and contraction of pilomotor muscles.
    (05 Mar 2000)
    alpha alcoholism Jellinek's term for a still controllable and strictly psychological dependence on alcohol, as to relieve emotional or physical pain, with resulting interference with interpersonal relationships.
    (05 Mar 2000)
    ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
    KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • Á¦Ç°¸í
      ¼ººÐ/ÇÔ·®
      ±¸ºÐ/º¸Çè±Þ¿©
    KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • Á¦Ç°¸í
      ¼ººÐ/ÇÔ·®
      ±¸ºÐ/º¸Çè±Þ¿©
    ¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    ¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
    ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
    ´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
    ´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
    ¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
    ¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
    ¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
    ¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
    ´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
    ´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
    ´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
      ÇÑÀÚ
    ´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
      ÇÑÀÚ
    ´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
    ´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
    ´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
    ´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
    KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
    KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
    KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ÄÚµå
      ¿µ¹®
      ÇѱÛ
    Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ÄÚµå
      ¿µ¹®
      ÇѱÛ
    °æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
      ¼³¸í
    CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
    MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
    ¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
    ¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
    ¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
    ¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
    ¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
    ¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
    ¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
    Á¦Ç°¸í
    ÆÇ¸Å»ç
    º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
    ¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
    Á¦Ç°¸í
    ÆÇ¸Å»ç
    º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
    ¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
    ¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
    ¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
    ¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
    KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
    ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    • ¿µ¹®
      ÇѱÛ
    WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
    ¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
    ¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
    ÅëÇÕ°Ë»ö ¿Ï·á